{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:19:15Z","timestamp":1770815955857,"version":"3.50.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010787","name":"Genome Alberta","doi-asserted-by":"publisher","award":["TMIC MC4"],"award-info":[{"award-number":["TMIC MC4"]}],"id":[{"id":"10.13039\/501100010787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"The Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["grant number FS 148461"],"award-info":[{"award-number":["grant number FS 148461"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000196","name":"The Canada Foundation for Innovation","doi-asserted-by":"crossref","award":["grant number MSIF 35456"],"award-info":[{"award-number":["grant number MSIF 35456"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"crossref"}]},{"name":"FORDECYT-PRONACES","award":["64382"],"award-info":[{"award-number":["64382"]}]},{"name":"INMEGEN internal funds","award":["Basal 2025"],"award-info":[{"award-number":["Basal 2025"]}]},{"DOI":"10.13039\/501100009051","name":"Secretar\u00eda de Salud","doi-asserted-by":"publisher","award":["FPIS2024-INMEGEN-6940"],"award-info":[{"award-number":["FPIS2024-INMEGEN-6940"]}],"id":[{"id":"10.13039\/501100009051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36756-z","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:04:13Z","timestamp":1768979053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of a five-metabolite and early-symptom profile with Parkinson\u2019s disease and its clinical progression"],"prefix":"10.1038","volume":"16","author":[{"given":"Juan Jos\u00e9","family":"Oropeza Valdez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Pedro","family":"Elizalde-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osbaldo Resendis","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaquelin Leyva","family":"-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Adalid-Peralta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayela","family":"Rodr\u00edguez-Violante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupasri","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Wishart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamil\u00e9","family":"L\u00f3pez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Mart\u00ednez","family":"-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"36756_CR1","doi-asserted-by":"publisher","unstructured":"Su, D. et al. Projections for prevalence of parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021. BMJ 388, https:\/\/doi.org\/10.1136\/bmj-2024-080952 (2025). https:\/\/www.bmj.com\/content\/388\/bmj-2024-080952.full.pdf.","DOI":"10.1136\/bmj-2024-080952"},{"key":"36756_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1440-1789.2007.00803.x","volume":"27","author":"K Wakabayashi","year":"2007","unstructured":"Wakabayashi, K., Tanji, K., Mori, F. & Takahashi, H. The lewy body in parkinson\u2019s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27, 494\u2013506. https:\/\/doi.org\/10.1111\/j.1440-1789.2007.00803.x (2007).","journal-title":"Neuropathology"},{"key":"36756_CR3","doi-asserted-by":"publisher","unstructured":"Dahabiyeh, L.\u00a0A., Nimer, R.\u00a0M., Rashed, M., Wells, J.\u00a0D. & Fiehn, O. Serum-based lipid panels for diagnosis of idiopathic parkinson\u2019s disease. Metabolites 13, https:\/\/doi.org\/10.3390\/metabo13090990 (2023).","DOI":"10.3390\/metabo13090990"},{"key":"36756_CR4","doi-asserted-by":"publisher","unstructured":"Ma, Z.-l. et al. Biomarkers of parkinson; disease: From basic research to clinical practice. Aging and disease 15, 1813\u20131830, https:\/\/doi.org\/10.14336\/ad.2023.1005 (2024).","DOI":"10.14336\/ad.2023.1005"},{"key":"36756_CR5","doi-asserted-by":"publisher","unstructured":"Lokhov, P.\u00a0G. et al. Application of clinical blood metabogram for diagnosis of early-stage parkinson\u2019s disease: a pilot study. Front. Mol. Biosci.\u00a0Volume 11 - 2024, https:\/\/doi.org\/10.3389\/fmolb.2024.1407974 (2024).","DOI":"10.3389\/fmolb.2024.1407974"},{"key":"36756_CR6","doi-asserted-by":"publisher","unstructured":"Luo, Y. et al. Global, regional, national epidemiology and trends of parkinson\u2019s disease from 1990 to 2021: findings from the global burden of disease study 2021. Front. Aging Neurosci.\u00a0Volume 16 - 2024, https:\/\/doi.org\/10.3389\/fnagi.2024.1498756 (2025).","DOI":"10.3389\/fnagi.2024.1498756"},{"key":"36756_CR7","unstructured":"Zafar, S. & Yaddanapudi, S.\u00a0S. Parkinson disease. In StatPearls [Internet] (StatPearls Publishing, Treasure Island (FL), 2025). Updated 2023 Aug 7."},{"key":"36756_CR8","doi-asserted-by":"publisher","unstructured":"Lanznaster, D., Dingeo, G., Samey, R.\u00a0A., Emond, P. & Blasco, H. Metabolomics as a crucial tool to develop new therapeutic strategies for neurodegenerative diseases. Metabolites 12, https:\/\/doi.org\/10.3390\/metabo12090864 (2022).","DOI":"10.3390\/metabo12090864"},{"key":"36756_CR9","doi-asserted-by":"publisher","unstructured":"Ostrakhovitch, E.\u00a0A., Ono, K. & Yamasaki, T.\u00a0R. Metabolomics in parkinson\u2019s disease and correlation with disease state. Metabolites 15, https:\/\/doi.org\/10.3390\/metabo15030208 (2025).","DOI":"10.3390\/metabo15030208"},{"key":"36756_CR10","doi-asserted-by":"publisher","first-page":"13888","DOI":"10.1038\/srep13888","volume":"5","author":"H Luan","year":"2015","unstructured":"Luan, H. et al. Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic parkinson\u2019s disease. Sci. Reports 5, 13888. https:\/\/doi.org\/10.1038\/srep13888 (2015).","journal-title":"Sci. Reports"},{"key":"36756_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208752","volume":"13","author":"D Willkommen","year":"2018","unstructured":"Willkommen, D. et al. Metabolomic investigations in cerebrospinal fluid of parkinson\u2019s disease. PLoS One 13, e0208752. https:\/\/doi.org\/10.1371\/journal.pone.0208752 (2018).","journal-title":"PLoS One"},{"key":"36756_CR12","doi-asserted-by":"publisher","unstructured":"Plewa, S. et al. The metabolomic approach reveals the alteration in human serum and cerebrospinal fluid composition in parkinson\u2019s disease patients. Pharm. (Basel) 14, https:\/\/doi.org\/10.3390\/ph14090935 (2021).","DOI":"10.3390\/ph14090935"},{"key":"36756_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00401-023-02616-7","volume":"146","author":"JM Judd","year":"2023","unstructured":"Judd, J. M. et al. Inflammation and the pathological progression of alzheimer\u2019s disease are associated with low circulating choline levels. Acta Neuropathol 146, 565\u2013583. https:\/\/doi.org\/10.1007\/s00401-023-02616-7 (2023).","journal-title":"Acta Neuropathol"},{"key":"36756_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41598-023-51034-y","volume":"14","author":"E Abdik","year":"2024","unstructured":"Abdik, E. & \u00c7akir, T. Transcriptome-based biomarker prediction for parkinson\u2019s disease using genome-scale metabolic modeling. Sci. Reports 14, 585. https:\/\/doi.org\/10.1038\/s41598-023-51034-y (2024).","journal-title":"Sci. Reports"},{"key":"36756_CR15","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1021\/acschemneuro.4c00355","volume":"15","author":"WT Santos","year":"2024","unstructured":"Santos, W. T. et al. Metabolomics unveils disrupted pathways in parkinson\u2019s disease: Toward biomarker-based diagnosis. ACS Chem. Neurosci. 15, 3168\u20133180. https:\/\/doi.org\/10.1021\/acschemneuro.4c00355 (2024).","journal-title":"ACS Chem. Neurosci."},{"key":"36756_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27422","volume":"10","author":"KF Yin","year":"2024","unstructured":"Yin, K. F. et al. Causal association and mediating effect of blood biochemical metabolic traits and brain image-derived endophenotypes on alzheimer\u2019s disease. Heliyon 10, e27422. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27422 (2024).","journal-title":"Heliyon"},{"key":"36756_CR17","doi-asserted-by":"publisher","unstructured":"Vardarajan, B. et al. Lysophosphatidylcholines are associated with p-tau181 levels in early stages of alzheimer\u2019s disease. Res Sq https:\/\/doi.org\/10.21203\/rs.3.rs-3346076\/v1 (2024).","DOI":"10.21203\/rs.3.rs-3346076\/v1"},{"key":"36756_CR18","doi-asserted-by":"publisher","unstructured":"Pan, X. et al. Plasma metabolites distinguish dementia with lewy bodies from alzheimer\u2019s disease: a cross-sectional metabolomic analysis. Front. Aging Neurosci.\u00a0Volume 15 - 2023, https:\/\/doi.org\/10.3389\/fnagi.2023.1326780 (2024).","DOI":"10.3389\/fnagi.2023.1326780"},{"key":"36756_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e30452","volume":"10","author":"LA Dahabiyeh","year":"2024","unstructured":"Dahabiyeh, L. A., Nimer, R. M., Wells, J. D., Abu-Rish, E. Y. & Fiehn, O. Diagnosing parkinson\u2019s disease and monitoring its progression: Biomarkers from combined gc-tof ms and lc-ms\/ms untargeted metabolomics. Heliyon 10, e30452. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30452 (2024).","journal-title":"Heliyon"},{"key":"36756_CR20","doi-asserted-by":"publisher","unstructured":"de Lope, E.\u00a0G. et al. Comprehensive blood metabolomics profiling of parkinson\u2019s disease reveals coordinated alterations in xanthine metabolism. npj Park. Dis.\u00a010, 68, https:\/\/doi.org\/10.1038\/s41531-024-00671-9 (2024).","DOI":"10.1038\/s41531-024-00671-9"},{"key":"36756_CR21","doi-asserted-by":"publisher","first-page":"14769","DOI":"10.3390\/ijms241914769","volume":"24","author":"M Ambeskovic","year":"2023","unstructured":"Ambeskovic, M. et al. Metabolomic signatures of alzheimer\u2019s disease indicate brain region-specific neurodegenerative progression. Int. J. Mol. Sci. 24, 14769 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"36756_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11306-023-02078-8","volume":"20","author":"JE Nielsen","year":"2024","unstructured":"Nielsen, J. E. et al. Serum metabolic signatures for alzheimer\u2019s disease reveal alterations in amino acid composition: a validation study. Metabolomics 20, 12. https:\/\/doi.org\/10.1007\/s11306-023-02078-8 (2024).","journal-title":"Metabolomics"},{"key":"36756_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s44324-024-00016-3","volume":"2","author":"A Schweickart","year":"2024","unstructured":"Schweickart, A. et al. Serum and csf metabolomics analysis shows mediterranean ketogenic diet mitigates risk factors of alzheimer\u2019s disease. NPJ Metab Health Dis 2, 15. https:\/\/doi.org\/10.1038\/s44324-024-00016-3 (2024).","journal-title":"NPJ Metab Health Dis"},{"key":"36756_CR24","doi-asserted-by":"publisher","unstructured":"Kimpara, T. & Takeda, A. Clinical diagnostic criteria for parkinson\u2019s disease. Neurol. Ther.\u00a037, 10\u201315, https:\/\/doi.org\/10.15082\/jsnt.37.1_10 (2020).","DOI":"10.15082\/jsnt.37.1_10"},{"key":"36756_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/wnl.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427\u201342. https:\/\/doi.org\/10.1212\/wnl.17.5.427 (1967).","journal-title":"Neurology"},{"key":"36756_CR26","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"Status and recommendations","year":"2003","unstructured":"Status and recommendations. Disease, M. D. S. T. F. o. R. S. f. P. The unified parkinson\u2019s disease rating scale (updrs). Mov. Disord. 18, 738\u2013750. https:\/\/doi.org\/10.1002\/mds.10473 (2003).","journal-title":"Mov. Disord."},{"key":"36756_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck, A. T., Ward, C. H., Mendelson, M., Mock, J. & Erbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry 4, 561\u201371. https:\/\/doi.org\/10.1001\/archpsyc.1961.01710120031004 (1961).","journal-title":"Arch Gen Psychiatry"},{"key":"36756_CR28","unstructured":"Schwab, R.\u00a0S. & England, A.\u00a0C. Projection technique for evaluating surgery in parkinson\u2019s disease. In Gillingham, F.\u00a0J. & Donaldson, I. M.\u00a0L. (eds.) Third Symposium on Parkinson\u2019s Disease, 152\u2013157 (E.\u00a0&\u00a0S.\u00a0Livingstone, Edinburgh, 1969)."},{"key":"36756_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/mds.20189","volume":"20","author":"M Proulx","year":"2005","unstructured":"Proulx, M., de Courval, F. P., Wiseman, M. A. & Panisset, M. Salivary production in parkinson\u2019s disease. Mov Disord 20, 204\u20137. https:\/\/doi.org\/10.1002\/mds.20189 (2005).","journal-title":"Mov Disord"},{"key":"36756_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.parkreldis.2014.08.013","volume":"20","author":"P Srivanitchapoom","year":"2014","unstructured":"Srivanitchapoom, P., Pandey, S. & Hallett, M. Drooling in parkinson\u2019s disease: a review. Park. Relat Disord 20, 1109\u201318. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.08.013 (2014).","journal-title":"Park. Relat Disord"},{"key":"36756_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mds.27862","volume":"35","author":"KR Chaudhuri","year":"2020","unstructured":"Chaudhuri, K. R. et al. The movement disorder society nonmotor rating scale: Initial validation study. Mov Disord 35, 116\u2013133. https:\/\/doi.org\/10.1002\/mds.27862 (2020).","journal-title":"Mov Disord"},{"key":"36756_CR32","doi-asserted-by":"publisher","first-page":"10627","DOI":"10.1021\/acs.analchem.0c01682","volume":"92","author":"J Zheng","year":"2020","unstructured":"Zheng, J., Zhang, L., Johnson, M., Mandal, R. & Wishart, D. S. Comprehensive targeted metabolomic assay for urine analysis. Anal. Chem. 92, 10627\u201310634. https:\/\/doi.org\/10.1021\/acs.analchem.0c01682 (2020).","journal-title":"Anal. Chem."},{"key":"36756_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/metabo14010041","volume":"14","author":"Y L\u00f3pez-Hern\u00e1ndez","year":"2024","unstructured":"L\u00f3pez-Hern\u00e1ndez, Y. et al. The urinary metabolome of newborns with perinatal complications. Metabolites 14, 41. https:\/\/doi.org\/10.3390\/metabo14010041 (2024).","journal-title":"Metabolites"},{"key":"36756_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s11306-025-02345-w","volume":"21","author":"A Zubkowski","year":"2025","unstructured":"Zubkowski, A. et al. Quantitative comparison of whole blood, plasma and serum metabolomes across different blood collection methods. Metabolomics 21, 146. https:\/\/doi.org\/10.1007\/s11306-025-02345-w (2025).","journal-title":"Metabolomics"},{"key":"36756_CR35","doi-asserted-by":"publisher","first-page":"14732","DOI":"10.1038\/s41598-021-94171-y","volume":"11","author":"Y L\u00f3pez-Hern\u00e1ndez","year":"2021","unstructured":"L\u00f3pez-Hern\u00e1ndez, Y. et al. Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for covid-19. Sci. Reports 11, 14732. https:\/\/doi.org\/10.1038\/s41598-021-94171-y (2021).","journal-title":"Sci. Reports"},{"key":"36756_CR36","doi-asserted-by":"publisher","unstructured":"Pang, Z. et al. Metaboanalyst\u00a06.0: Towards a unified platform for metabolomics data processing, analysis and interpretation. Nucleic Acids Res.\u00a052, W398\u2013W406, https:\/\/doi.org\/10.1093\/nar\/gkae253 (2024).","DOI":"10.1093\/nar\/gkae253"},{"key":"36756_CR37","first-page":"2171","volume":"13","author":"F-A Fortin","year":"2012","unstructured":"Fortin, F.-A., De Rainville, F.-M., Gardner, M.-A., Parizeau, M. & Gagn\u00e9, C. DEAP: Evolutionary algorithms made easy. J. Mach. Learn. Res. 13, 2171\u20132175 (2012).","journal-title":"J. Mach. Learn. Res."},{"key":"36756_CR38","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F. et al. Scikit-learn: Machine learning in Python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn. Res."},{"key":"36756_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. Matplotlib: A 2d graphics environment. Comput. Sci. & Eng. 9, 90\u201395. https:\/\/doi.org\/10.1109\/MCSE.2007.55 (2007).","journal-title":"Comput. Sci. & Eng."},{"key":"36756_CR40","doi-asserted-by":"publisher","unstructured":"Waskom, M.\u00a0L. seaborn: statistical data visualization. J. Open Source Softw.\u00a06, 3021, https:\/\/doi.org\/10.21105\/joss.03021 (2021).","DOI":"10.21105\/joss.03021"},{"key":"36756_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/brain\/awm304","volume":"131","author":"M Bogdanov","year":"2008","unstructured":"Bogdanov, M. et al. Metabolomic profiling to develop blood biomarkers for parkinson\u2019s disease. Brain 131, 389\u2013396. https:\/\/doi.org\/10.1093\/brain\/awm304 (2008).","journal-title":"Brain"},{"key":"36756_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jnnp-2014-309676","volume":"87","author":"T Hatano","year":"2015","unstructured":"Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P. & Hattori, N. Identification of novel biomarkers for parkinson\u2019s disease by metabolomic technologies. J. Neurol. Neurosurg. & Psychiatry 87, 295\u2013301. https:\/\/doi.org\/10.1136\/jnnp-2014-309676 (2015).","journal-title":"J. Neurol. Neurosurg. & Psychiatry"},{"key":"36756_CR43","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1212\/WNL.0000000000003663","volume":"88","author":"PA LeWitt","year":"2017","unstructured":"LeWitt, P. A., Li, J., Lu, M., Guo, L. & Auinger, P. Metabolomic biomarkers as strong correlates of parkinson disease progression. Neurology 88, 862\u2013869. https:\/\/doi.org\/10.1212\/WNL.0000000000003663 (2017).","journal-title":"Neurology"},{"key":"36756_CR44","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/mds.26992","volume":"32","author":"F Burt\u00e9","year":"2017","unstructured":"Burt\u00e9, F. et al. Metabolic profiling of parkinson\u2019s disease and mild cognitive impairment. Mov. Disord. 32, 927\u2013932. https:\/\/doi.org\/10.1002\/mds.26992 (2017).","journal-title":"Mov. Disord."},{"key":"36756_CR45","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/mds.27173","volume":"32","author":"W Han","year":"2017","unstructured":"Han, W., Sapkota, S., Camicioli, R., Dixon, R. A. & Li, L. Profiling novel metabolic biomarkers for parkinson\u2019s disease using in-depth metabolomic analysis. Mov. Disord. 32, 1720\u20131728. https:\/\/doi.org\/10.1002\/mds.27173 (2017).","journal-title":"Mov. Disord."},{"key":"36756_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jchromb.2018.01.025","volume":"1081\u20131082","author":"H Zhao","year":"2018","unstructured":"Zhao, H. et al. Potential biomarkers of parkinson\u2019s disease revealed by plasma metabolic profiling. J. Chromatogr. B 1081\u20131082, 101\u2013108. https:\/\/doi.org\/10.1016\/j.jchromb.2018.01.025 (2018).","journal-title":"J. Chromatogr. B"},{"key":"36756_CR47","doi-asserted-by":"publisher","unstructured":"Stoessel, D. et al. Promising metabolite profiles in the plasma and csf of early clinical parkinson\u2019s disease. Front. Aging Neurosci.\u00a010, https:\/\/doi.org\/10.3389\/fnagi.2018.00051 (2018).","DOI":"10.3389\/fnagi.2018.00051"},{"key":"36756_CR48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/acn3.724","volume":"6","author":"A Okuzumi","year":"2019","unstructured":"Okuzumi, A. et al. Metabolomics-based identification of metabolic alterations in PARK2. Annals Clin. Transl. Neurol. 6, 525\u2013536. https:\/\/doi.org\/10.1002\/acn3.724 (2019).","journal-title":"Annals Clin. Transl. Neurol."},{"key":"36756_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2019.110766","volume":"128","author":"A Picca","year":"2019","unstructured":"Picca, A. et al. Circulating amino acid signature in older people with parkinson\u2019s disease: A metabolic complement to the EXosomes in parkinson disease ( EXPAND) study. Exp. Gerontol. 128, 110766. https:\/\/doi.org\/10.1016\/j.exger.2019.110766 (2019).","journal-title":"Exp. Gerontol."},{"key":"36756_CR50","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3233\/JPD-191896","volume":"10","author":"S Molsberry","year":"2020","unstructured":"Molsberry, S. et al. Plasma metabolomic markers of insulin resistance and diabetes and rate of incident parkinson\u2019s disease. J. Park. Dis 10, 1011\u20131021. https:\/\/doi.org\/10.3233\/JPD-191896 (2020).","journal-title":"J. Park. Dis"},{"key":"36756_CR51","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/diagnostics10050332","volume":"10","author":"PG Lokhov","year":"2020","unstructured":"Lokhov, P. G., Trifonova, O. P., Maslov, D. L., Lichtenberg, S. & Balashova, E. E. Diagnosis of parkinson\u2019s disease by a metabolomics-based laboratory-developed test (ldt). Diagnostics 10, 332. https:\/\/doi.org\/10.3390\/diagnostics10050332 (2020).","journal-title":"Diagnostics"},{"key":"36756_CR52","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11011-020-00665-5","volume":"36","author":"M-X Dong","year":"2021","unstructured":"Dong, M.-X., Wei, Y.-D. & Hu, L. Lipid metabolic dysregulation is involved in parkinson\u2019s disease dementia. Metab.\u00a0Brain Dis. 36, 463\u2013470. https:\/\/doi.org\/10.1007\/s11011-020-00665-5 (2021).","journal-title":"Metab.\u00a0Brain Dis."},{"key":"36756_CR53","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.parkreldis.2021.09.014","volume":"91","author":"SM Albillos","year":"2021","unstructured":"Albillos, S. M. et al. Plasma acyl-carnitines, bilirubin, tyramine and tetrahydro-21-deoxycortisol in parkinson\u2019s disease and essential tremor: A case-control biomarker study. Park. & Relat. Disord. 91, 167\u2013172. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.09.014 (2021).","journal-title":"Park. & Relat. Disord."},{"key":"36756_CR54","doi-asserted-by":"publisher","unstructured":"Talavera And\u00fajar, B.\u00a0n. et al. Studying the parkinson\u2019s disease metabolome and exposome in biological samples through different analytical and cheminformatics approaches: A pilot study. Anal. Bioanal. Chem.\u00a0414, 7399\u20137419, https:\/\/doi.org\/10.1007\/s00216-022-04207-z (2022).","DOI":"10.1007\/s00216-022-04207-z"},{"key":"36756_CR55","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1021\/acscentsci.2c01468","volume":"9","author":"JD Zhang","year":"2023","unstructured":"Zhang, J. D., Xue, C., Kolachalama, V. B. & Donald, W. A. Interpretable machine learning on metabolomics data reveals biomarkers for parkinson\u2019s disease. ACS Cent. Sci. 9, 1035\u20131045. https:\/\/doi.org\/10.1021\/acscentsci.2c01468 (2023).","journal-title":"ACS Cent. Sci."},{"key":"36756_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106698","volume":"202","author":"F Carrillo","year":"2024","unstructured":"Carrillo, F. et al. Multiomics approach discloses lipid and metabolite profiles associated with parkinson\u2019s disease stages and applied therapies. Neurobiol. Dis. 202, 106698. https:\/\/doi.org\/10.1016\/j.nbd.2024.106698 (2024).","journal-title":"Neurobiol. Dis."},{"key":"36756_CR57","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3390\/molecules30040850","volume":"30","author":"K Tkachenko","year":"2025","unstructured":"Tkachenko, K., Gonz\u00e1lez-S\u00e1iz, J. M. & Pizarro, C. Untargeted lipidomics reveals potential biomarkers in plasma samples for the discrimination of patients affected by parkinson\u2019s disease. Molecules 30, 850. https:\/\/doi.org\/10.3390\/molecules30040850 (2025).","journal-title":"Molecules"},{"key":"36756_CR58","doi-asserted-by":"publisher","unstructured":"Liu, S. et al. Unraveling the relation of parkinson\u2019s disease and metabolites: A combined analysis of stool and plasma metabolites based on untargeted metabolomics technology. CNS Neurosci. & Ther.31, \u2014, https:\/\/doi.org\/10.1111\/cns.70424 (2025).","DOI":"10.1111\/cns.70424"},{"key":"36756_CR59","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1007\/s12035-017-0845-3","volume":"55","author":"K-H Chang","year":"2018","unstructured":"Chang, K.-H. et al. Alterations of metabolic profile and kynurenine metabolism in the plasma of parkinson\u2019s disease. Mol.\u00a0Neurobiol. 55, 6319\u20136328. https:\/\/doi.org\/10.1007\/s12035-017-0845-3 (2018).","journal-title":"Mol.\u00a0Neurobiol."},{"key":"36756_CR60","doi-asserted-by":"publisher","unstructured":"D\u2019Andrea, G. et al. Different circulating trace amine profiles in De Novo and treated parkinson\u2019s disease patients. Sci.\u00a0Reports 9, \u2014, https:\/\/doi.org\/10.1038\/s41598-019-42535-w (2019).","DOI":"10.1038\/s41598-019-42535-w"},{"key":"36756_CR61","doi-asserted-by":"publisher","unstructured":"Klatt, S. et al. A six-metabolite panel as potential blood-based biomarkers for parkinson\u2019s disease. npj Park. Dis.\u00a07, 94, https:\/\/doi.org\/10.1038\/s41531-021-00239-x (2021).","DOI":"10.1038\/s41531-021-00239-x"},{"key":"36756_CR62","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/cells11030395","volume":"11","author":"K-H Chang","year":"2022","unstructured":"Chang, K.-H. et al. Alterations of sphingolipid and phospholipid pathways and ornithine level in the plasma as biomarkers of parkinson\u2019s disease. Cells 11, 395. https:\/\/doi.org\/10.3390\/cells11030395 (2022).","journal-title":"Cells"},{"key":"36756_CR63","doi-asserted-by":"publisher","unstructured":"D\u2019Ascenzo, N. et al. Metabolomics of blood reveals age-dependent pathways in parkinson\u2019s disease. Cell & Biosci.\u00a012, \u2014, https:\/\/doi.org\/10.1186\/s13578-022-00831-5 (2022).","DOI":"10.1186\/s13578-022-00831-5"},{"key":"36756_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.585584","volume":"14","author":"J Wang","year":"2020","unstructured":"Wang, J., Wang, F., Mai, D. & Qu, S. Molecular mechanisms of glutamate toxicity in parkinson\u2019s disease. Front. Neurosci. 14, 585584. https:\/\/doi.org\/10.3389\/fnins.2020.585584 (2020).","journal-title":"Front. Neurosci."},{"key":"36756_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147129","volume":"11","author":"EC Schulte","year":"2016","unstructured":"Schulte, E. C. et al. Alterations in lipid and inositol metabolisms in two dopaminergic disorders. PLOS ONE 11, e0147129. https:\/\/doi.org\/10.1371\/journal.pone.0147129 (2016).","journal-title":"PLOS ONE"},{"key":"36756_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.135626","volume":"745","author":"M-X Dong","year":"2021","unstructured":"Dong, M.-X., Hu, L., Wei, Y.-D. & Chen, G.-H. Metabolomics profiling reveals altered lipid metabolism and identifies a panel of lipid metabolites as biomarkers for parkinson\u2019s disease related anxiety disorder. Neurosci. Lett. 745, 135626. https:\/\/doi.org\/10.1016\/j.neulet.2021.135626 (2021).","journal-title":"Neurosci. Lett."},{"key":"36756_CR67","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.3390\/cells9112394","volume":"9","author":"A Yilmaz","year":"2020","unstructured":"Yilmaz, A. et al. Metabolic profiling of csf from people suffering from sporadic and LRRK2 parkinson\u2019s disease: A pilot study. Cells 9, 2394. https:\/\/doi.org\/10.3390\/cells9112394 (2020).","journal-title":"Cells"},{"key":"36756_CR68","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cca.2020.08.005","volume":"510","author":"S Kumari","year":"2020","unstructured":"Kumari, S. et al. Identification of potential urine biomarkers in idiopathic parkinson\u2019s disease using NMR. Clin. Chimica Acta 510, 442\u2013449. https:\/\/doi.org\/10.1016\/j.cca.2020.08.005 (2020).","journal-title":"Clin. Chimica Acta"},{"key":"36756_CR69","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1039\/c5mb00711a","volume":"12","author":"A Wuolikainen","year":"2016","unstructured":"Wuolikainen, A. et al. Multi-platform mass spectrometry analysis of the csf and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, parkinson\u2019s disease and control subjects. Mol. BioSystems 12, 1287\u20131298. https:\/\/doi.org\/10.1039\/c5mb00711a (2016).","journal-title":"Mol. BioSystems"},{"key":"36756_CR70","doi-asserted-by":"publisher","unstructured":"Nagesh Babu, G. et al. Serum metabolomics study in a group of parkinson\u2019s disease patients from northern india. Clin. Chimica Acta 480, 214\u2013219, https:\/\/doi.org\/10.1016\/j.cca.2018.02.022 (2018).","DOI":"10.1016\/j.cca.2018.02.022"},{"key":"36756_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.147118","volume":"1748","author":"B Toczylowska","year":"2020","unstructured":"Toczylowska, B., Zieminska, E., Michalowska, M., Chalimoniuk, M. & Fiszer, U. Changes in the metabolic profiles of the serum and putamen in parkinson\u2019s disease patients - In Vitro and In Vivo NMR spectroscopy studies. Brain Res. 1748, 147118. https:\/\/doi.org\/10.1016\/j.brainres.2020.147118 (2020).","journal-title":"Brain Res."},{"key":"36756_CR72","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","volume":"32","author":"MM Unger","year":"2016","unstructured":"Unger, M. M. et al. Short chain fatty acids and gut microbiota differ between patients with parkinson\u2019s disease and age-matched controls. Park. & Relat. Disord. 32, 66\u201372. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.08.019 (2016).","journal-title":"Park. & Relat. Disord."},{"key":"36756_CR73","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13073-017-0428-y","volume":"9","author":"JR Bedarf","year":"2017","unstructured":"Bedarf, J. R. et al. Functional implications of microbial and viral gut metagenome changes in early-stage L-dopa-na\u00efve parkinson\u2019s disease patients. Genome Medicine 9, 39. https:\/\/doi.org\/10.1186\/s13073-017-0428-y (2017).","journal-title":"Genome Medicine"},{"key":"36756_CR74","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"Y Shao","year":"2021","unstructured":"Shao, Y. et al. Comprehensive metabolic profiling of parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol. Neurodegener. 16, 4. https:\/\/doi.org\/10.1186\/s13024-021-00425-8 (2021).","journal-title":"Mol. Neurodegener."},{"key":"36756_CR75","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00415-025-13138-5","volume":"272","author":"PJ Oliver","year":"2025","unstructured":"Oliver, P. J., Civitelli, L. & Hu, M. T. The gut-brain axis in early parkinson\u2019s disease: From prodrome to prevention. J.\u00a0Neurol. 272, 1477\u20131492. https:\/\/doi.org\/10.1007\/s00415-025-13138-5 (2025).","journal-title":"J.\u00a0Neurol."},{"key":"36756_CR76","doi-asserted-by":"publisher","unstructured":"Saiki, S. et al. Decreased long-chain acylcarnitines from insufficient \u03b2-oxidation as potential early diagnostic markers for parkinson\u2019s disease. Sci. Reports 7, 1389. https:\/\/doi.org\/10.1038\/s41598-017-06767-y (2017).","DOI":"10.1038\/s41598-017-06767-y"},{"key":"36756_CR77","doi-asserted-by":"publisher","unstructured":"Zhang, H., Cao, F., Yu, J., Liang, Y. & Wu, Y. Investigating plasma lipid profiles in association with parkinson\u2019s disease risk. npj Park. Dis.\u00a011, 7, https:\/\/doi.org\/10.1038\/s41531-025-00955-8 (2025).","DOI":"10.1038\/s41531-025-00955-8"},{"key":"36756_CR78","doi-asserted-by":"publisher","first-page":"1424056","DOI":"10.3389\/fnagi.2024.1424056","volume":"16","author":"Y Qin","year":"2024","unstructured":"Qin, Y. et al. Plasma lipidome, circulating inflammatory proteins, and parkinson\u2019s disease: A mendelian randomisation study. Front. Aging Neurosci. 16, 1424056. https:\/\/doi.org\/10.3389\/fnagi.2024.1424056 (2024).","journal-title":"Front. Aging Neurosci."},{"key":"36756_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.8595","volume":"34","author":"J Mileti\u0107 Vukajlovi\u0107","year":"2020","unstructured":"Mileti\u0107 Vukajlovi\u0107, J. et al. Increased plasma phosphatidylcholine\/lysophosphatidylcholine ratios in patients with parkinson\u2019s disease. Rapid Commun. Mass Spectrom. 34, e8595. https:\/\/doi.org\/10.1002\/rcm.8595 (2020).","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"36756_CR80","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s41598-018-37657-6","volume":"9","author":"J Fagotti","year":"2019","unstructured":"Fagotti, J. et al. Chronic sleep restriction in the rotenone parkinson\u2019s disease model in rats reveals peripheral early-phase biomarkers. Sci. Reports 9, 1898. https:\/\/doi.org\/10.1038\/s41598-018-37657-6 (2019).","journal-title":"Sci. Reports"},{"key":"36756_CR81","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nm.3466","volume":"20","author":"M Mapstone","year":"2014","unstructured":"Mapstone, M. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Medicine 20, 415\u2013418. https:\/\/doi.org\/10.1038\/nm.3466 (2014).","journal-title":"Nat. Medicine"},{"key":"36756_CR82","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3390\/biomedicines9121944","volume":"9","author":"K-H Chang","year":"2021","unstructured":"Chang, K.-H. et al. Altered metabolic profiles of the plasma of patients with amyotrophic lateral sclerosis. Biomedicines 9, 1944 (2021).","journal-title":"Biomedicines"},{"key":"36756_CR83","doi-asserted-by":"publisher","unstructured":"Luo, X., Liu, Y., Balck, A., Klein, C. & Fleming, R.\u00a0M.\u00a0T. Identification of metabolites reproducibly associated with parkinson\u2019s disease via meta-analysis and computational modelling. npj Park. Dis.\u00a010, 38, https:\/\/doi.org\/10.1038\/s41531-024-00732-z (2024).","DOI":"10.1038\/s41531-024-00732-z"},{"key":"36756_CR84","doi-asserted-by":"publisher","unstructured":"Kaleck\u00fd, K. & Bottiglieri, T. Targeted metabolomic analysis in parkinson\u2019s disease brain frontal cortex and putamen with relation to cognitive impairment. npj Park. Dis.\u00a09, 84, https:\/\/doi.org\/10.1038\/s41531-023-00531-y (2023).","DOI":"10.1038\/s41531-023-00531-y"},{"key":"36756_CR85","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211. https:\/\/doi.org\/10.1016\/S0197-4580(02)00065-9 (2003).","journal-title":"Neurobiol. Aging"},{"key":"36756_CR86","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/mdc3.12454","volume":"4","author":"N Malek","year":"2016","unstructured":"Malek, N. et al. Autonomic dysfunction in early parkinson\u2019s disease: Results from the united kingdom tracking parkinson\u2019s study. Mov. Disord. Clin. Pract. 4, 509\u2013516. https:\/\/doi.org\/10.1002\/mdc3.12454 (2016).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"36756_CR87","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s13311-020-00897-4","volume":"17","author":"RF Pfeiffer","year":"2020","unstructured":"Pfeiffer, R. F. Autonomic dysfunction in parkinson\u2019s disease. Neurotherapeutics 17, 1464\u20131479. https:\/\/doi.org\/10.1007\/s13311-020-00897-4 (2020).","journal-title":"Neurotherapeutics"},{"key":"36756_CR88","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/jpm15050172","volume":"15","author":"L Pe\u00f1a-Zelayeta","year":"2025","unstructured":"Pe\u00f1a-Zelayeta, L. et al. Redefining non-motor symptoms in parkinson\u2019s disease. J. Pers. Medicine 15, 172. https:\/\/doi.org\/10.3390\/jpm15050172 (2025).","journal-title":"J. Pers. Medicine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36756-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36756-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36756-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T10:11:39Z","timestamp":1770804699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36756-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36756"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36756-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5885"}}